There is no excerpt because this is a protected post.
Though not positively aligned with a rising long-term interest rate environment, maybe BioPharma has anticipated the bump in yields and bottomed. We’ll see. But one
As you surely know, they don’t all work this way. But trading GILD has been like clockwork for me since buying the lows in June.
You could say GILD replaced ABBV after I took its profit and now ABBV is back after I took GILD’s profit. It may sound slick,
It’s been a great run off the June bottom and now all Biotech profits are booked. I’ll hold general Healthcare for now, with all individual
As to the post’s title, I have no idea. What I do know is that a nice profit is in the books on a suddenly
Yesterday we got the surge and then the ease into the close. Today? Err… The weekly now targets 350, barring a harsh reversal over the
Gilead (GILD) has hit the target laid out in this NFTRH+ post from April. As I often do, I sold below the target but for
Personally, I am leaning slightly toward bearish on the stock market, but the Biotech sector has been going to its own beat. Taken in a
 post unlocked to give public readers an idea of how NFTRH manages the entirety of the market (not just special interests like precious metals,